NeuroTherapia
Latest round
- Series B
Last raised
- Aug 2024
Total raised
- $21M
Investors
- 7
About NeuroTherapia
Founded in 2015 and based in Ohio, US, NeuroTherapia, Inc. operates as a clinical-stage company that focuses on developing new chemical entities for the treatment of neuroinflammatory diseases. The company was co-founded by Drs. Mohamed Naguib and Joseph Foss. As of 2024, the company is headed by its CEO Tony Giordano. In August 2024, NeuroTherapia, Inc. The firm concentrated on creating small molecule oral medicines that target known CNS inflammatory drivers, microglia cells. The company's main initiative, NTRX-07, is a tiny chemical that may be taken orally that is intended to improve learning and memory by enhancing neuroplasticity and reducing inflammation.
Who invested in NeuroTherapia
7 investors across 2 rounds
See all investors in NeuroTherapia
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about NeuroTherapia
Who invested in NeuroTherapia?
NeuroTherapia has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has NeuroTherapia raised?
NeuroTherapia has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did NeuroTherapia last raise money?
NeuroTherapia's most recent round on record is a Series B, in Aug 2024.
What does NeuroTherapia do?
Founded in 2015 and based in Ohio, US, NeuroTherapia, Inc.
Where is NeuroTherapia headquartered?
NeuroTherapia is headquartered in Cleveland, US.
Which VCs invest in companies like NeuroTherapia?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at NeuroTherapia's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like NeuroTherapia? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.